Prothena Corp Public (PRTA) Non Operating Income (2013 - 2026)
Prothena Corp Public (PRTA) posted quarterly Non Operating Income of $2.7 million for Q1 2026, down 36.15% year-over-year from $4.2 million in Q1 2025, and up 2.4% quarter-over-quarter from $2.6 million in Q4 2025.
Prothena Corp Public (PRTA) Non Operating Income (2013 - 2026) Analysis & Trends
Prothena Corp Public's Non Operating Income history runs 14 years deep, the most recent figure standing at $2.7 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 36.15% year-over-year to $2.7 million; the TTM figure through Mar 2026 stood at $12.3 million (down 45.98% YoY), while the FY2025 annual figure was $13.8 million, down 46.12% from the prior year.
- Non Operating Income for Q1 2026 stood at $2.7 million, up from $2.6 million in the prior quarter.
- The five-year high for Non Operating Income was $8.5 million in Q3 2023, with the low at -$17000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $4.2 million (2025), against an average of $4.6 million.
- Peak annual rise in Non Operating Income reached 85525.0% in 2022, while the deepest fall reached 150.0% in 2022.
- Prothena Corp Public's Non Operating Income stood at $3.4 million in 2022, then soared by 131.11% to $7.9 million in 2023, then plunged by 31.67% to $5.4 million in 2024, then tumbled by 51.37% to $2.6 million in 2025, then gained by 2.4% to $2.7 million in 2026.
- Business Quant data shows PRTA's Non Operating Income at $2.7 million in Q1 2026, $2.6 million in Q4 2025, and $3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | 2.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.52 Mn |
| Mar 31, 2026 | 2.69 Mn |
| Dec 31, 2025 | 2.62 Mn |
| Sep 30, 2025 | 3.33 Mn |
| Jun 30, 2025 | 3.65 Mn |
| Mar 31, 2025 | 4.21 Mn |
| Dec 31, 2024 | 5.40 Mn |
| Sep 30, 2024 | 6.68 Mn |
| Jun 30, 2024 | 6.47 Mn |
| Mar 31, 2024 | 7.09 Mn |
| Dec 31, 2023 | 7.90 Mn |
| Sep 30, 2023 | 8.51 Mn |
| Jun 30, 2023 | 7.60 Mn |
| Mar 31, 2023 | 6.55 Mn |
| Dec 31, 2022 | 3.42 Mn |
| Sep 30, 2022 | 1.92 Mn |
| Jun 30, 2022 | 637,000.00 |
| Mar 31, 2022 | -17,000.00 |
| Dec 31, 2021 | -4,000.00 |
| Sep 30, 2021 | -31,000.00 |